Eflornithine

Base Information

• Chemical Name: Eflornithine
• CAS No.: 67037-37-0
• Molecular Formula: C6H12F2N2O2
• Molecular Weight: 182.16800
• Mol file: 67037-37-0.mol

Synonyms:2-(Difluoromethyl)-DL-ornithine;BRN 2250529;CCRIS 3718;D,L-alpha-Difluoromethylornithine;DL-alpha-Difluoromethylornithine;UNII-ZQN1G5V6SR;DL-Ornithine, 2-(difluoromethyl)-;

Chemical Property of Eflornithine

Chemical Property:

• Appearance/Colour: powder
• Vapor Pressure: 9.72E-06mmHg at 25°C
• Refractive Index: 1.462
• Boiling Point: 347oC at 760 mmHg
• Flash Point: 163.7oC
• PSA: 89.34000
• Density: 1.293g/cm3
• LogP: 1.17310
• Storage Temp.: -15°C

Purity/Quality:

99% ^*data from raw suppliers

EFLORNITHINE 95.00% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Indications: Because of its high cost, need of repeated intravenous administration and the relatively large quantities of the drug needed for each patient eflornithine use will be associated with major difficulties in rural Africa. Currently it is only recommended in patients with late-stage Trypanosoma brucei gambiense sleeping sickness refractory to melarsoprol. Eflornithine (difluoromethyl ornithine, Ornidyl) is a unique antiprotozoal agent in that its mode of action involves inhibition of a specific enzyme, ornithine decarboxylase. In eukaryotes, decarboxylation of ornithine is required for biosynthesis of polyamines, which are important in cell division and differentiation. Eflornithine is given intravenously, and about 80% of the drug is excreted in the urine within 24 hours. It does not bind significantly to plasma proteins and has a terminal plasma half-life of about 3 hours. It crosses the blood-brain barrier and is one of the drugs of choice for treating the hemolymphatic and meningoencephalitic stage of T. brucei-gambiense. The most significant side effects are anemia and leukopenia. Oral therapy is associated with considerable gastrointestinal toxicity. Diarrhea, thrombocytopenia, and seizures are occasionally reported.
• Description: Metcalf et al.reported the synthesis of eflornithine (difluoromethyl ornithine [DFMO]) in 1978. Their interest arose from the desire to prepare ornithine decarboxylase (ODC) inhibitors as tools for studying the role of polyamines as regulators of growth processes. Ornithine decarboxylase catalyzes the conversion of ornithine to putrescine (1,4-diaminobutane), which in turn leads to the formation of the polyamines, spermine, and spermidine. It was not until 1980 that Bacchi et al. demonstrated the potential of DFMO in the treatment of trypanosomiasis.
• Uses: Labelled Eflornithine. Irreversible inhibitor of ornithine decarboxylase, an enzyme involved in polyamine biosynthesis. Antineoplastic; antipneumocystic; antiprotozoal (Trypanosoma). Used in the treatment of hirsutism. Eflornithine is an irreversible inhibitor of ornithine decarboxylase that blocks putrescine biosynthesis in T. brucei in vitro and inhibits the growth and multiplication of the parasite in vivo. The drug, administered orally or parenterally, is relatively nontoxic and is effective in eliminating the parasite T. b. rhodesiense and, to a greater extent, T. b. gambiense. Eflornithine was approved for human use by the FDA in late 1990. Side effects associated with oral administration are diarrhea, nausea, and vomiting. There is a significant relapse rate. A mixture of eflornithine (5) and nifurtimox (6, C10H13N3O5S, Lampit, Bayer 2502) shows good activity against T. b. gambiense. The former compound is also reported to potentiate the effect of melarsoprol in infected mice.
• Clinical Use: Eflornithine is used for the treatment of West African sleepingsickness, caused by Trypanosoma brucei gambiense.It is specifically indicated for the meningoencephaliticstage of the disease. Eflornithine is a myelosuppressivedrug that causes high incidences of anemia, leukopenia,and thrombocytopenia. Complete blood cell counts must bemonitored during the course of therapy.The irreversible inactivation of ornithine decarboxylaseby eflornithine is accompanied by decarboxylation andrelease of fluoride ion from the inhibitor, suggesting enzyme-catalyzed activation of the inhibitor. Only the (—) isomer,stereochemically related to L-ornithine, is active.Eflornithine is supplied as the hydrochloride salt. It may beadministered either intravenously or orally. Approximately80% of the unchanged drug is excreted in the urine.Penetration of eflornithine into the CSF is facilitated by inflammationof the meninges.